表紙
市場調查報告書

乾癬性關節炎 - 醫藥品的全球市場的預測與分析

Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 927255
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
乾癬性關節炎 - 醫藥品的全球市場的預測與分析 Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年01月31日內容資訊: 英文 130 Pages
簡介

乾癬性關節炎,是乾癬相關的慢性性的關節症。對患者進行了五個疾病領域的評估(末梢關節炎,軸性疾病,肌腱炎,手指炎,指甲、皮膚病變)。由於臨床症狀的多樣性,有診斷和治療困難的情況。

本報告提供乾癬性關節炎的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,促進因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢與過去趨勢
  • 預測手法
  • 乾癬性關節炎的流行病學預測
  • 討論

第6章 疾病的管理

  • 診斷、治療概要
  • 美國
  • EU5個國家
  • 日本

第7章 競爭評估

  • 概要
  • 生物相似藥

第8章 未滿足需求和機會的評估

  • 概要
  • 臨床醫生的認識提高
  • 早期且更正確的診斷
  • 醫藥品的安全性和有效性的改善
  • 治療獲取的改善

第9章 開發平台評估

  • 概要
  • 臨床開發中的有潛力醫藥品
  • 其他開發中的醫藥品

第10章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • AbbVie
  • Pfizer
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • UCB
  • Amgen
  • Novartis
  • Eli Lilly
  • Gilead
  • Sun Pharma
  • 協和麒麟

第11章 市場預測

第12章 附錄

目錄
Product Code: GDHC186PIDR

Psoriatic arthritis (PsA) is a chronic form of arthropathy commonly associated with psoriasis. Patients are evaluated on five disease domains: peripheral arthritis, axial disease, enthesitis, dactylitis, and nail and skin involvement. Due to the heterogeneity of clinical symptoms, PsA can be difficult to diagnose and treat.

Current therapies for disease management include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), injectable immuno-suppressants and oral small molecule therapies. Of these, intravenous and subcutaneous therapies targeting tumor necrosis factor (anti-TNFs) have been the gold standard of care for almost 20 years. However, other mechanisms of action have gained traction in recent years. Over the forecast period, market growth is expected to be driven primarily by the approval and launch of five pipeline therapies. However, this growth will likely be curtailed by the erosion of branded agents sales by biosimilars and generics in the second half of the forecast period.

Key Highlights:

  • The greatest drivers of growth in the global PsA market include the launch of five new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the PsA market include low diagnostic and treatment rates as well as low patient compliance and persistence.
  • Among the late-stage pipeline products, two are injectable anti-interleukin therapies and three are oral Janus Kinase (JAK) inhibitors.
  • The most important unmet needs in the PsA market are increased access to therapies as well as therapies that can target the multiple disease domains.

KEY QUESTIONS ANSWERED:

  • Which unmet needs are limiting the treatment of PsA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for PsA? How should these strategies differ across different geographical markets?
  • What effect will the launch of biosimilars and generics have on the sales of branded agents? What can drug manufacturers do in order to ensure the success of their biosimilars?
  • What are the main R&D trends in the PsA market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope:

  • Overview of PsA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline PsA market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsA therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global PsA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsA therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Psoriatic Arthritis: Executive Summary

  • 2.1 PsA Market to Experience Moderate Growth from 2018-2028
  • 2.2 Oral Therapeutics Dominate the Late-Stage PsA Pipeline
  • 2.3 Opportunities Remain for More Cost-Effective and Targeted Treatments
  • 2.4 Convenient and Affordable Pipeline Agents Poised to Perform Well in a Crowded PsA Market
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Sources Not Used
  • 5.5 Epidemiological Forecast for Psoriatic Arthritis (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of PsA
    • 5.5.2 Diagnosed Prevalent Cases of PsA
    • 5.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA
    • 5.5.4 Age-Specific Diagnosed Prevalent Cases of PsA
    • 5.5.5 Diagnosed Prevalent Cases of PsA by Severity
    • 5.5.6 Diagnosed Prevalent Cases of PsA with Psoriasis
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
    • 6.1.1 Diagnostic Scales
    • 6.1.2 Treatment Guidelines by Market
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview
    • 7.1.1 TNF Inhibitors
    • 7.1.2 IL-17 Inhibitors
    • 7.1.3 IL-23 Inhibitors
    • 7.1.4 Janus Kinase Inhibitors
    • 7.1.5 Other Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs
  • 7.2 Biosimilars

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Increased Clinician Awareness of PsA
  • 8.3 Earlier and More Accurate PsA Diagnoses
  • 8.4 Improved Drug Safety and Efficacy Across All Disease Domains
  • 8.5 Improved Access to Therapies

9 Pipeline Assessment

  • 9.1 Overview
    • 9.1.1 IL-17 Inhibitors
    • 9.1.2 IL-23 Inhibitors
    • 9.1.3 JAK Inhibitors
  • 9.2 Promising Drugs in Clinical Development
  • 9.3 Other Drugs in Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 AbbVie
  • 10.4 Pfizer
  • 10.5 Johnson & Johnson
  • 10.6 Bristol-Myers Squibb
  • 10.7 UCB
  • 10.8 Amgen
  • 10.9 Novartis
  • 10.10 Eli Lilly
  • 10.11 Gilead
  • 10.12 Sun Pharma
  • 10.13 Kyowa Hakko Kirin

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Psoriatic Arthritis: Key Metrics in the 7MM
  • Table 2: Risk Factors and Comorbidities for PsA
  • Table 3: Classification Systems in PsA
  • Table 4: Treatment Guidelines for PsA by Market
  • Table 5: Country Profile - US
  • Table 6: Country Profile - 5EU
  • Table 7: Country Profile - Japan
  • Table 8: Leading Treatments for Psoriatic Arthritis, 2019
  • Table 9: Marketed Biosimilars for PsA, 2019
  • Table 10: 7MM, Non-Responsive Patients by Drug Class, All Severities, 2019
  • Table 11: AbbVie's Disease Portfolio Assessment, 2020
  • Table 12: Pfizer's Disease Portfolio Assessment, 2020
  • Table 13: J&J's Disease Portfolio Assessment, 2020
  • Table 14: Bristol-Myer's Squibb Disease Portfolio Assessment, 2020
  • Table 15: UCB's Disease Portfolio Assessment, 2020
  • Table 16: Amgen's Disease Portfolio Assessment, 2020
  • Table 17: Novartis' Disease Portfolio Assessment, 2020
  • Table 18: Eli Lilly's Disease Portfolio Assessment, 2020
  • Table 19: Gilead Disease Portfolio Assessment, 2020
  • Table 20: SunPharma's Disease Portfolio Assessment, 2020
  • Table 21: Kyowa Hakko Kirin's Disease Portfolio Assessment, 2020
  • Table 22: PsA Market - Global Drivers and Barriers, 2018-2028
  • Table 23: Key Events Impacting Sales for PsA in the US, 2018-2028
  • Table 24: PsA Market - Drivers and Barriers in the US, 2018-2028
  • Table 25: Key Events Impacting Sales for PsA in the 5EU, 2018-2028
  • Table 26: PsA Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 27: Key Events Impacting Sales for PsA in Japan, 2018-2028
  • Table 28: Psoriatic Arthritis Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 29: Key Historical and Projected Launch Dates for PsA
  • Table 30: Key Projected Patent Expiry Dates for PsA
  • Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for PsA in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in PsA During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for PsA, 2020
  • Figure 4